awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q55035826-8F0FBCA6-70B0-4A75-924F-BB38125496A6
Q55035826-8F0FBCA6-70B0-4A75-924F-BB38125496A6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55035826-8F0FBCA6-70B0-4A75-924F-BB38125496A6
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
P2860
Q55035826-8F0FBCA6-70B0-4A75-924F-BB38125496A6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55035826-8F0FBCA6-70B0-4A75-924F-BB38125496A6
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
eb2097aff9bcfc5dd30b8e18045a7c56b2d06f67
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer